RxDoctor Payments Data

Archana Rastogi, MD

Family Medicine · Huntsville, ALNPI 1427047885

Payments from drug & device makers

$5,939in general payments, 2019–2025

Across 143 payments — averaging $41.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$3K
  • AstraZeneca$790
  • Novo Nordisk$589
  • Astellas Pharma US Inc$492
  • GSK$242
  • Bayer$176
  • plus $787 from 14 others

What the payments were for

  • Food & beverage$2,68186%
  • Education$42914%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,939 in reported general payments places this provider in the 85th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$91,880
Medicare patients
224
Services billed
1,632

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin30$32,485
EliquisApixaban18$29,791
FarxigaDapagliflozin Propanediol18$23,074
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$21,343
OzempicSemaglutide18$20,705
LinzessLinaclotide16$17,414
MyrbetriqMirabegron12$12,940
Synjardy XrEmpagliflozin/Metformin Hcl11$10,732
JanuviaSitagliptin Phosphate13$7,870
Lantus SolostarInsulin Glargine,hum.Rec.Anlog29$5,238
Gabapentin278$2,767
Atorvastatin Calcium202$2,608
Pravastatin Sodium118$1,605
Pantoprazole Sodium118$1,601
Losartan Potassium127$1,550

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr$33$43,21741 claims
PfizerEliquis, Paxlovid$28$31,15029 claims
AstraZenecaFarxiga$790$23,07418 claims
GSKTrelegy Ellipta$242$21,34314 claims
Novo NordiskOzempic$589$20,70518 claims
Astellas Pharma US IncMyrbetriq$492$12,94012 claims
MerckJanuvia$29$7,87013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Huntsville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →